North America Anti diabetic Biosimilars Market: By Drug Class -IV Inhibitors, ?-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type, By Distribution Channel and Country

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

North America Anti diabetic Biosimilars Market: By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, ?-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)and Country

checked icon arrow_drop_down
checked icon Single User License $3100 $2480
checked icon Multiple User License $4600 $3680
checked icon Corporate User License $6900 $5520

North America Anti diabetic Biosimilars Market size was valued at US$ x billion in 2022 and is expected to reach US$ x billion by 2029, at a CAGR of x% from 2023-2029. Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.

North America Anti diabetic Biosimilars Market Dynamics

Increase in the prevalence of diabetic patients. Patent expiries block buster drugs and promising product pipeline. Rise in R&D activities for the innovation of Insulin biosimilars Restraints: High cost of R&D activities. Stringent regulatory policies. Complexity in development of biosimilars

North America Anti Diabetic Biosimilars Market Segmentation Analysis

Report Benchmarks

Details

By Drug Class

  • Insulin
  • Biguanides
  • Sulfonyl Ureas
  • Thiazolidinediones
  • Di Peptidyl Peptidase (DPP)-IV Inhibitors
  • glucosidase Inhibitos
  • GLP-1 Agonists
  • Others

By Disease Type

  • Type-I Diabetes
  • Type-II Diabetes

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The key segments covered in the North America Anti diabetic Biosimilars Market are: by Drug Class, Disease Type, Distribution Channel

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.North America Anti diabetic Biosimilars Market Introduction 
2.1.North America Anti diabetic Biosimilars Market  - Taxonomy
2.2.North America Anti diabetic Biosimilars Market  - Definitions
2.2.1.Drug Class
2.2.2.Disease Type
2.2.3.Distribution Channel 
2.2.4.Region
3.North America Anti diabetic Biosimilars Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.North America Anti diabetic Biosimilars Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.North America Anti diabetic Biosimilars Market  By Drug Class, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Insulin
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Biguanides
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Sulfonyl Ureas
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Thiazolidinediones
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. glucosidase Inhibitos
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. GLP-1 Agonists
5.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
5.8. Others
5.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.8.3. Market Opportunity Analysis 
6.North America Anti diabetic Biosimilars Market  By Disease Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Type-I Diabetes
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Type-II Diabetes
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.North America Anti diabetic Biosimilars Market  By Distribution Channel , 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.North America Anti diabetic Biosimilars Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
9.North America Anti diabetic Biosimilars Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Insulin
9.1.2.Biguanides
9.1.3.Sulfonyl Ureas
9.1.4.Thiazolidinediones
9.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
9.1.6.glucosidase Inhibitos
9.1.7.GLP-1 Agonists
9.1.8.Others
9.2.  Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Type-I Diabetes
9.2.2.Type-II Diabetes
9.3.  Distribution Channel  Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
9.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10 Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Type-I Diabetes
10.2.2.Type-II Diabetes
10.1.  Distribution Channel  Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
10.2.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11. Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Type-I Diabetes
11.2.2.Type-II Diabetes
11.1  Distribution Channel  Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
11.2.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.  Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Type-I Diabetes
12.2.2.Type-II Diabetes
12.1.  Distribution Channel  Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
12.2.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1  Disease Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.2.Type-I Diabetes
12.2.3.Type-II Diabetes
13.  Distribution Channel  Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
13.1.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Boehringer Ingelheim GmbH 
14.2.2.Eli Lilly & Co. 
14.2.3.Sanofi-aventis U.S. LLC
14.2.4.Samsung Bioepis (Samsung BioLogics) 
14.2.5.Mylan N.V. 
14.2.6.Wockhardt 
15. Research Methodology 
16. Appendix and Abbreviations 

 

Key Market Players

  • Boehringer Ingelheim GmbH 
  • Eli Lilly & Co. 
  • Sanofi-aventis U.S. LLC
  • Samsung Bioepis (Samsung BioLogics) 
  • Mylan N.V. 
  • Wockhardt 

Related Industry Reports

Chronic Refractory Gout Pharmaceuticals Market

Familial Mediterranean Fever Pharmaceuticals Market

Australia Point of Care Diagnostics Market

Aseptic Sampling Market